AKT1 and non-small cell lung carcinoma: Notably, 8aa potently inhibited the EGFR and EGFR-mediated signaling pathways such as AKT and ERK1/2 in a dose-dependent manner, and it also showed selective reductions in cell viability against human NSCLC cell lines PC9 and A549.